Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by Leerink Partnrs

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating for the company in a report on Tuesday. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Leerink Partners restated a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,118.62.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $1,031.15 on Tuesday. The company’s 50 day simple moving average is $1,130.96 and its two-hundred day simple moving average is $1,034.01. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals has a 1 year low of $769.19 and a 1 year high of $1,211.20. The stock has a market capitalization of $113.62 billion, a PE ratio of 30.46, a P/E/G ratio of 3.72 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the company earned $8.79 earnings per share. Analysts predict that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold a total of 9,270 shares of company stock worth $10,695,833 in the last 90 days. Company insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of REGN. Gilbert & Cook Inc. grew its stake in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after acquiring an additional 146 shares during the period. TrinityPoint Wealth LLC grew its position in Regeneron Pharmaceuticals by 4.8% in the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares during the period. D.A. Davidson & CO. grew its holdings in shares of Regeneron Pharmaceuticals by 17.0% in the fourth quarter. D.A. Davidson & CO. now owns 709 shares of the biopharmaceutical company’s stock worth $623,000 after acquiring an additional 103 shares during the period. US Bancorp DE lifted its holdings in Regeneron Pharmaceuticals by 6.7% in the fourth quarter. US Bancorp DE now owns 4,941 shares of the biopharmaceutical company’s stock valued at $4,340,000 after acquiring an additional 310 shares during the period. Finally, Congress Wealth Management LLC DE bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $271,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.